跳至主要内容
临床试验/NCT01240161
NCT01240161已完成不适用

Personalized Translational Platform for Biomarker Discovery in Brain Tumors

Marcelo F. Di Carli, MD, FACC2 个研究点 分布在 1 个国家目标入组 37 人开始时间: 2009年12月最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
已完成
发起方
入组人数
37
试验地点
2
主要终点
Overall Survival

研究概览

简要总结

The central hypothesis for this proposal is that multimodal (clinical, imaging, tissue) biomarkers will better predict early brain tumor response to treatments and will be more reliable prognostic markers in patients with malignant brain tumors.

研究设计

研究类型
Observational
观察模型
Case Only
时间视角
Prospective

入排标准

年龄范围
18 Years 至 85 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Newly diagnosed or suspected high grade glioma ≥ 1cm in diameter on postoperative anatomic imaging (contrast MRI), prior to initiation of chemoXRT
  • Anticipated survival ≥6 months
  • Able to give informed consent
  • Capable of undergoing MRI and PET scans without the need for sedation or general anesthesia
  • Male or Female

排除标准

  • Prior radiation therapy and chemotherapy to the brain
  • Active intracranial infection or nonglial brain mass.
  • Recent large intracranial hemorrhage (<1 month)
  • Expected survival <6 months
  • Pregnant or nursing
  • Renal failure
  • Lives far from BWH and/or is unwilling/ unable to return for scheduled imaging visits.

结局指标

主要结局

Overall Survival

时间窗: 7 months

Progression free Survival

时间窗: 7 months

MRI and clinical criteria

次要结局

未报告次要终点

研究者

发起方
Marcelo F. Di Carli, MD, FACC
申办方类型
Other
责任方
Sponsor Investigator
主要研究者

Marcelo F. Di Carli, MD, FACC

Chief of Nuclear Medicine/PET

Brigham and Women's Hospital

研究点 (2)

Loading locations...

相似试验